Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 17, 2022

Associations of Gadolinium-Based Contrast Agent Exposures With Physical and Cognitive Disability in MS

Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging
Gadolinium-based contrast agent exposures and physical and cognitive disability in multiple sclerosis
J Neuroimaging 2022 Oct 01;[EPub Ahead of Print], K Nakamura, MP McGinley, SE Jones, MJ Lowe, JA Cohen, PM Ruggieri, D Ontaneda

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading